An Ascending, Single and Multiple Dose(s), Double-Blind, Randomized, Placebo Controlled Study Assessing the Safety, Tolerability, and Pharmacokinetics of OV329 in Healthy Male and Female Participants
Clinical Trial Grant
Awarded By
Ovid Therapeutics
Start Date
December 2, 2022
End Date
September 25, 2024
Awarded By
Ovid Therapeutics
Start Date
December 2, 2022
End Date
September 25, 2024